NCT03242967View on ClinicalTrials.gov

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2017

Primary Completion Date

February 12, 2018

Study Completion Date

February 12, 2018

Conditions
AnemiaDialysis-Dependent Chronic Kidney Disease
Interventions
DRUG

Vadadustat

Oral tablet

DRUG

Darbepoetin alfa

subcutaneous or intravenous

Trial Locations (1)

91324

Research Site, Northridge

Sponsors
All Listed Sponsors
lead

Akebia Therapeutics

INDUSTRY

NCT03242967 - Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) | Biotech Hunter | Biotech Hunter